Related Experiment Video
Updated: May 13, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma
Katia Mancuso1,2, Simona Barbato1,2, Francesco Di Raimondo3
1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", 40138 Bologna, Italy.
Managing relapsed/refractory multiple myeloma, especially after lenalidomide failure, presents challenges. New therapeutic strategies are emerging to improve outcomes for these difficult-to-treat patients.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- The multiple myeloma therapeutic landscape has evolved, improving patient survival and response depth.
- Relapsed/refractory multiple myeloma poses challenges, with prior treatment influencing subsequent choices.
- Lenalidomide refractoriness is linked to poorer outcomes, necessitating specific management strategies.
Purpose of the Study:
- To review current treatment options for lenalidomide-refractory multiple myeloma.
- To discuss emerging therapies and future directions for this patient subgroup.
Main Methods:
- Literature review of current treatment guidelines.
- Analysis of recent clinical trial data for relapsed/refractory multiple myeloma.
- Discussion of therapeutic strategies based on available evidence.
Main Results:
- Treatment options for lenalidomide-refractory multiple myeloma are limited but expanding.
- Recent clinical research shows promising results for novel therapeutic approaches.
- Management of patients refractory to multiple agents remains a critical unmet need.
Conclusions:
- Optimizing treatment for lenalidomide-refractory multiple myeloma is crucial.
- Emerging therapies offer hope for improved outcomes in this challenging patient population.
- Ongoing clinical trials are vital for advancing the care of relapsed/refractory multiple myeloma.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy
Drugs that Destabilize Microtubules

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)